OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, May 16, 2012

paywalled - Unravelling the two entities of endometrioid ovarian cancer: A single center clinical experience



Unravelling the two entities of endometrioid ovarian cancer: A single center clinical experience



Abstract

Objective

Due to the increasing prevalence of the benign condition, ovarian carcinoma arising from endometriosis is emerging as a relevant clinical entity with an unclear biological signature. We have investigated clinical and histologic features of endometriosis-associated endometrioid ovarian cancer using an institutional retrospective database.

Methods

Patients diagnosed with endometrioid ovarian cancer at our institution were divided into two groups according to the fulfillment or not of Sampson's and Scott's criteria for the detection of endometriosis-associated ovarian cancer. Clinical and histological data were reported and compared. Survival analysis was obtained using the log-rank test in an unadjusted Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards regression model to establish independent factors associated with endometriosis-associated endometrioid ovarian cancer and to identify predictors of survival.

Results

Patients with endometriosis-associated endometrioid ovarian cancer were significantly younger, had a lower disease stage (77% vs 38%; p = 0.003), a less prevalent high grade tumor (38% vs 82%; p = 0.002) and a higher prevalence of squamous and mucinous metaplasia

The rate of endometrial cancer diagnosis was significantly higher in women with endometriosis-associated endometrioid ovarian cancer (33%) than in other patients (11%) (p = 0.04) with a 92% concordance between ovarian and endometrial histologic tumor grade. A significant difference in survival rate could not be demonstrated between patients with or without endometriosis.

Conclusions

The analysis of a retrospective endometrioid ovarian cancer database may allow to suggest a molecular, morphological and clinical parallelism between endometrial and endometrioid ovarian cancer.

Highlights

► Endometriosis-associated endometrioid ovarian tumors possess a different biologic signature when compared to cancers not associated with the disease.
► Clinical course and molecular alterations of type I and type II endometrial tumors are similar to those detected respectively in endometriosis-associated and non-associated endometrioid ovarian tumor.

Journal of Ovarian Research May 15th: Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis



 Blogger's Note: included in the study are references to hereditary ovarian cancer - BRCA's but not Lynch Syndrome
                                      ~~~~~~~~~~~~~~~

Journal of Ovarian Research Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis

Introduction
Ovarian cancer is the fifth leading cause of cancer death in US women [1], yet primary prevention recommendations are limited. Gynecological surgeries including tubal ligation and hysterectomy may alter ovarian cancer risk by protecting the ovary from ascending carcinogens or damaging the utero-ovarian artery altering hormonal function. In addition, tubal ligation may increase immunity against the surface glycoprotein human mucin 1 (MUC1) [2-4]. While tubal ligation and hysterectomy generally have been found to be inversely associated with ovarian cancer, effect estimates vary between studies and little is
known about potential effect modifiers of these associations. Therefore, we conducted a meta-analysis of the association between ovarian cancer and tubal ligation as well as hysterectomy.

Results
......In secondary analyses, the association between tubal ligation and ovarian cancer risk was stronger for endometrioid tumors compared to serous tumors.

Conclusion

Observational epidemiologic evidence strongly supports that tubal ligation and hysterectomy are associated with a decrease in the risk of ovarian cancer, by approximately 26-30%. Additional research is needed to determine whether the association between tubal ligation and hysterectomy on ovarian cancer risk differs by individual, surgical, and tumor characteristics.

pdf


What Did You Know, and When Did You Stop Knowing It? - Forbes



What Did You Know, and When Did You Stop Knowing It? - Forbes

Recently, a story (Analytical Trend Troubles Scientists) appeared in The Wall Street Journal that was critical of — what turns out to be — an increasingly common type of medical investigation: the observational study.

The WSJ story uses as its jumping-off point the (shocking? surprising?) discrepancy between two studies that both asked the same question and used the same data: does taking bisphosphonates (think Fosamax) increase your risk of stomach or throat cancer?

One study concluded that no, it does not significantly increase your cancer risk. The other said that yes, it does significantly increase said risk. ["Significantly" here means "probably", in the statistician's sense.] In neither case, though, did it find that your cancer risk would be particularly high: 0.1% vs 0.2% in 60/69-year-olds. So why the dustup?.....

DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1



DcR3 binds to ovarian cancer via heparan sulfateproteoglycans and modulates tumor cells response toplatinum with corresponding alteration in theexpression of BRCA1

Background
Overcoming platinum resistance is a major obstacle in the treatment of Epithelial Ovarian Cancer (EOC). In our previous work Decoy Receptor 3 (DcR3) was found to be related to platinum resistance. The major objective of this work was to define the cellular interaction of DcR3 with EOC and to explore its effects on platinum responsiveness.

Conclusions
Non-malignant cells contribute to the high levels of DcR3 in ovarian cancer. DcR3 binds readily to EOC cells via HSPGs and alter their responsiveness to platinum chemotherapy.The paradoxical responses seen were related to the expression pattern of HSPGs available on the cells surface to interact with. Although the mechanism behind this is not completely known alterations in DNA repair pathways including the expression of BRCA1 appear to be involved.

Tuesday, May 15, 2012

Inflammatory Breast Cancer: What We Know and What We Need to Learn



Inflammatory Breast Cancer: What We Know and What We Need to Learn:

Abstract

Purpose. We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease.
Design. We performed a comprehensive review of the English-language literature on IBC through computerized literature searches.
Results. Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography–computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (~30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC.
Conclusion. Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.

paywalled: Sex Differences in Fertility-Related Information Received by Young Adult Cancer Survivors (ages 18-45 yrs/includes ovarian cancer))



Sex Differences in Fertility-Related Information Received by Young Adult Cancer Survivors [Treatment-Related Complications]:

Purpose
The aim was to investigate male and female cancer survivors' perception of fertility-related information and use of fertility preservation (FP) in connection with cancer treatment during reproductive age.

Conclusion
Our results show marked sex differences regarding the receipt of fertility-related information and use of FP. There is an urgent need to develop fertility-related information adapted to female patients with cancer to improve their opportunities to participate in informed decisions regarding their treatment and future reproductive ability.

paywalled: Potential Usefulness of Single Nucleotide Polymorphisms to Identify Persons at High Cancer Risk: An Evaluation of Seven Common Cancers [Statistics in Oncology]



Potential Usefulness of Single Nucleotide Polymorphisms to Identify Persons at High Cancer Risk: An Evaluation of Seven Common Cancers [Statistics in Oncology]:

Purpose
To estimate the likely number and predictive strength of cancer-associated single nucleotide polymorphisms (SNPs) that are yet to be discovered for seven common cancers.

Methods
From the statistical power of published genome-wide association studies, we estimated the number of undetected susceptibility loci and the distribution of effect sizes for all cancers. Assuming a log-normal model for risks and multiplicative relative risks for SNPs, family history (FH), and known risk factors, we estimated the area under the receiver operating characteristic curve (AUC) and the proportion of patients with risks above risk thresholds for screening. From additional prevalence data, we estimated the positive predictive value and the ratio of non–patient cases to patient cases (false-positive ratio) for various risk thresholds.

Results
Age-specific discriminatory accuracy (AUC) for models including FH and foreseeable SNPs ranged from 0.575 for ovarian cancer to 0.694 for prostate cancer. The proportions of patients in the highest decile of population risk ranged from 16.2% for ovarian cancer to 29.4% for prostate cancer. The corresponding false-positive ratios were 241 for colorectal cancer, 610 for ovarian cancer, and 138 or 280 for breast cancer in women age 50 to 54 or 40 to 44 years, respectively.

Conclusion
Foreseeable common SNP discoveries may not permit identification of small subsets of patients that contain most cancers. Usefulness of screening could be diminished by many false positives. Additional strong risk factors are needed to improve risk discrimination.

Monday, May 14, 2012

Dr Rob Lamberts blog: Zen and the Art of Not Thinking Magically - Don't assume anything



Zen and the Art of Not Thinking Magically:

By Rob Lamberts, MD

Don’t assume anything.

Assumptions can kill.  Assuming something regarding your own health care can cost you money, cause you pain, and yes, even kill you.  Here’s my list of potentially harmful assumptions:

1.  No news is good news
If you have a test done and don’t hear anything about the result, do not assume it is fine.  This assumption kills people.  I have too many patients with too much information flying at me every day for me to catch every important detail.  Sometimes things are missed, but sometimes the results don’t come to our office.   We have trained our patients to expect an email or letter with their results within a certain amount of time, so they sometimes call when the test results don’t come in.  I tell them to do so in the clinical summary sheet I hand out at the end of each visit, but the assumption remains.
Always know what tests are being run, and always get the results of those tests (in writing, if possible).

2.  The doctor will think I am stupid
I often have patients apologizing to me.  They apologize when they have a “weird” symptom, when they “ask too many questions,” when they stop taking a medication due to side-effects, and when they are really, really worried about something.  They seem afraid that I am going to roll my eyes and think of them as “one of those patients” – the kind that I complain about to my office staff.
I hate it when people apologize.  Apologies assume there is some standard or expectation that a person is not meeting, and the only expectations that I have of my patients is:

a. they have or want to prevent medical problems
b. They want my help.

Why should I get mad at people for either of these things, as it is the job of a doctor to help people who need them.  I know there are doctors out there who treat patients like bad kids or like they are morons, but those doctors are out of step with reality.  They are the morons.  I don’t apologize to the barber that my hair grew.  I don’t apologize to my accountant for having tax questions.  Understand your position as the paying customer; get what you paid for.

One warning on this one: viewing yourself as a customer cuts both ways.  If you have the right to get what you pay for, the doctor has the right to be paid for what they give you.  People often think docs should do what they do out of pure charity and kindness, which is wrong.  I may expect the mechanic to be kind and charitable, but I should also expect to pay them for what they do.  This means that expecting your doctor to spend 30 minutes with you and only charge you for a 5-minute visit is not fair to the doctor (or his wife and kids).

3.  Doctors don’t want to be questioned
I hope I am not unusual in this, but I would rather have patients question what I do than to accept everything I say.
Patients’ questions help me in several ways.  First, they let me know what I am not explaining well enough.  I think people follow instructions better when they understand them, so if you don’t understand what I said, ask.  Second, questions build my credibility.  If I can explain the reason for my recommendations, I am more trusted.  If I fear questions, then it looks like I am hiding something.  Third, and most importantly, questions sometimes lead to better care.  Sometimes patients ask me about something I haven’t considered.  Sometimes the questions make me think things through and see my faulty logic.  Sometimes questions make me look for information and learn something.
Good doctoring has a whole lot of teaching in it.  Teaching is not a goal in itself, however; the goal is to get the person being taught to understand.  If you don’t understand what’s being done, why you got a prescription, or what your diagnosis is, ask.  If you wonder about another possible diagnosis, ask.  If your doctor doesn’t like you asking questions, ask for a copy of your records and find another doctor.

4.  Standard care is the right care.
Much of what doctors do is based on, or at least consistent with science; but a lot of care goes on despite that science says otherwise.  A group of physician organizations recently banded together and published the Choosing Wisely Campaign, a set of “things patients and physicians should question.”  The groups urge doctors and patients to choose care that is:
  • Supported by evidence
  • Not duplicative of other tests or procedures already received
  • Free from harm
  • Truly necessary
Here’s a sample of things done frequently that the Choosing Wisely campaign suggests questioning:
  • Getting an x-ray for people with uncomplicated back pain
  • Using antibiotics for sinusitis lasting less than 7 days
  • Routine EKG’s on average (lower-risk) people
  • Routine screening stress-tests
  • Use of anti-inflammatory drugs (NSAID’s) in people with high blood pressure, heart disease, kidney problems, or diabetes.
There are many more recommendations on the site, but the reason this campaign was launched was because of how often these rules are broken.  I must admit, I have had to change my habits in the light of some of these recommendations.

5.  My doctors talk to each other
I am a primary care doctor, so I am supposed to be the hub of a patient’s care.  If a patient of mine goes in the hospital, has surgery, sees a specialist, or goes to the emergency room, I am supposed to be notified.  Unfortunately, this is probably not even true in of 50% of these situations.  Even when patients ask specifically to have records sent to me, they often aren’t there.
Specialists also have this problem, often getting consults without a clear reason.  Often this is a problem at the referring physician’s end, but we have had numerous specialists turn down offers to access our records.  We have also offered access to our records by hospitalists and ER doctors, only to be been turned down.  Many doctors prefer to give care with only information they gather.  It is rare that any doctor has all of the information that may be helpful.
An exception to this is the integrated care system run by a hospital (usually), in which doctors all share medical records.  Clearly the sharing of information in that setting is better than in my world, but being under the care of a hospital gives other disadvantages I will discuss later.

6.  My doctor has accurate records
Not only do I not have much of the information that comes from other doctors, but the information I do have in my records are not always accurate.  The biggest culprit in our office is old information that doesn’t get taken off.  It takes a large amount of time to make sure a person’s records are accurate, and there are no insurance companies willing to pay for improved accuracy.  So accuracy only happens when doctors take time away from reimbursed patient care and work to organize the records.  Again, our office makes a valiant effort at keeping things accurate, but I have found that it takes a huge amount of time, planning, and energy to keep records updated.
I personally don’t think this will change until the patient becomes responsible to keep their own records.  Nobody will ever care about a patient’s records as much as the patient does.  In the mean-time, I recommend that you keep an updated list of your medications, surgeries, problems, and even your family/home situation and bring it with you to visits.

7.  I will be notified when things are due
Are you due for a colonoscopy, thyroid lab tests, a follow-up CT scan, or a diabetic eye exam?  Most people don’t know exactly when things are due, and many assume they will be notified when this is the case.  Gastroenterologists do often call when the follow-up colonoscopy is due, and mammography facilities sometimes call for a follow-up, but these are exceptions to this rule.  Doctors often say “repeat test in six months,” and then expect the patient to call to schedule after six months.  Even patients coming into the office may not be reminded of overdue tests, mainly due to the disorganization of medical records (#3 above).  If you think you might be due for something, ask.  Even asking the question, “are there any tests or labs I am due to get done?” can help remind providers to check for these things.  Remember, it is incredibly hard to keep records organize, so don’t assume your doctor’s office will act anything like Jiffy-Lube.

8.  Hospitals care
The commercials boast of how local hospitals are “there for you when you need them most,” and “your advocate for your health.”  This is horse hockey.  The people in the hospital may be caring and kind.  The doctors, nurses, and even administrators may want you to be healthy.  But the hospital is a business which requires people to be sick and have lots of procedures done to be profitable.  Most health care dollars are spent in hospitals, and many times those dollars do no good to the patient.  I’ve seen end-stage cancer patients get heart catheterization, people with dementia spend weeks in the ICU, and countless other procedures are done with no benefit (other than income to the hospital).
Don’t be fooled.  Your goal is to stay healthy and stay out of the hospital;  your doing so is bad for the business of hospitals.

9.  More is better
I have patients frequently asking for tests they don’t need.  Shouldn’t people get yearly lab panels?  Shouldn’t kids get their cholesterol checked?  What about those screening mobile tests for carotid artery plaques or PAD?  It’s hard to make my patients understand that in saying “no” to tests, I am being a better doctor.  I talked about this in an earlier post, but it bears repeating.  If someone has a high chance of having a condition, screening for it is useless (doing a strep test on someone with an obvious strep throat).  If someone has a very low chance of having a condition, screening for it won’t reduce the risk (CA-125 screening for ovarian cancer, for example).  Having more information is often not helpful, can lead to unnecessary worry or further testing, and costs a lot of money for no gain.  I don’t want more information, I want the right information.

10.  New is better
What about that new drug advertised on TV?  What about the surgery done by robots?  Should I take that antidepressant for pain?  Do I have low-T?  Should I go to the hospital with the brand new 200 gazillion dollar heart pavilion? Always look at advertising with a skeptical eye.  The main reason businesses spend money on advertising is that they want to make more money when you use the thing they advertised.  The 200 gazillion dollars for the heart pavilion has to come from somewhere.  There’s a reason why you first heard of “low T” on television and not from your doctor: the company who wants to fix your T wants your money.  Robotic surgery is surely cool, but it is also really expensive to buy that machine, and hospitals need you to want the “cool” surgery so they can pay for those machines.
Sometimes “new and improved” is a truthful boast, but usually it is a means into your wallet.

Rob Lamberts, MD, is a primary care physician practicing somewhere in the southeastern United States. He blogs regularly at More Musings (of a Distractible Kind). Where this post first appeared.

ESO: e-grandround May 24th: Biomarkers and candidate therapeutics in ovarian cancer pipeline



Biomarkers and candidate therapeutics in ovarian cancer pipeline

e-grandround

Biomarkers and candidate therapeutics in ovarian cancer pipeline CME accredited

e-grandround GR197 - 24 May 2012 - 18:15-19:00 CET

Expert: Hani Gabra, Imperial College, London, United Kingdom
Discussant: Margaret Hutka, Royal Marsden Hospital, Sutton, United Kingdom

The live session starts in about 9 days

Access to the live session is open 15 minutes before the start of the session
Submit your question in advance

An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers (OVA1)



An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers

Dr. Zhang is the inventor of the OVA1 algorithm, and as such is entitled to royalty payments from the sale of OVA1® through a license agreement between Johns Hopkins University and Vermillion, Inc.

Main Points
  • The advantages of an in vitro diagnostic multivariate index assay (IVDMIA) in comparison to a single biomarker assay are based on the premise that the single-valued index, with its aggregated information from complementary biomarkers, will outperform each of its component biomarkers used individually.
  • The ability of multivariate models to capture complex patterns in high-dimensional data also means that non-disease-related artifacts that happen to confound the samples used to train the models will also be captured.
  • The inclusion of biomarkers in an IVDMIA requires that they are complementary, and that they collectively outperform a single marker with respect to the test’s intended use.
  • OVA1® (Vermillion, Inc., Austin, TX) combines results from five tests—CA-125 II, prealbumin, apolipoprotein A-1, β2-microglobulin, and transferrin—into a single-valued index between 0 and 10; a higher value corresponds to a higher risk of malignancy.
  • The addition of OVA1 to clinical assessment brings significant improvement in sensitivity. This is, however, at the cost of a reduced specificity. During the construction of the OVA1 multivariate model and the choice of cutoff values, a conscious decision was made to emphasize the need for a high sensitivity. This decision took into consideration the need to mitigate the safety concern of OVA1 with respect to its predefined intended use. Because OVA1 is to be used prior to the decision to refer to a specialist, a high sensitivity minimizes the risk of false-negative results for patients who actually have malignant diseases.

paywalled - Contraception - Reproductive factors in relation to ovarian cancer: a case–control study in Northern Vietnam



ScienceDirect.com - Contraception - Reproductive factors in relation to ovarian cancer: a case–control study in Northern Vietnam

Abstract

Background

Ovarian cancer, one of the most common cancers in women and the most serious gynecologic cancer, is known to be influenced by reproductive factors, but these factors have not previously been examined in Vietnamese women.

PLoS ONE: European American Stratification in Ovarian Cancer Case Control Data: The Utility of Genome-Wide Data for Inferring Ancestry



Blogger's Note: interesting article includes migration of peoples from Europe to North America/s; ovarian cancer and genome

PLoS ONE: European American Stratification in Ovarian Cancer Case Control Data: The Utility of Genome-Wide Data for Inferring Ancestry

paywalled: Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study



Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study

The primary objective of this study was to assess the expression of cyclin E in tumour tissues from 661 patients with epithelial ovarian tumours. The second was to evaluate whether cyclin E tissue expression levels correlate with clinico-pathological parameters and prognosis of the disease. Using tissue arrays (TA), we analysed the cyclin E expression levels in tissues from 168 women with borderline ovarian tumours (BOT) (147 stage I, 4 stage II, 17 stage III) and 493 Ovarian cancer (OC) patients (127 stage I, 45 stage II, 276 stage III, 45 stage IV). Using a 10% cut-off level for cyclin E overexpression, 20% of the BOTs were positive with a higher proportion of serous than mucinous tumours. Sixty-two per cent of the OCs were positive for cyclin E expression with the highest percentage found in clear cell carcinomas

Results based on univariate and multivariate survival analyses with a 10% cut-off value showed that cyclin E had no independent prognostic value. In conclusion, we found cyclin E expression in tumour tissue to be of limited prognostic value to Danish OC patients.

open access: original paper - Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience - Cross - 2011 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library



Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience - Cross - 2011 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library

Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience

  1. PA Cross1, et al
Article first published online: 6 SEP 2011
DOI: 10.1111/j.1471-0528.2011.03129.x

Correspondence: re - Intra-operative frozen section analysis for suspected early-stage ovarian cancer - Twigg - 2012 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library



Intra-operative frozen section analysis for suspected early-stage ovarian cancer - Twigg - 2012 - BJOG: An International Journal of Obstetrics & Gynaecology

Volume 119, Issue 7, page 896, June 2012
Sir,
We read with interest the article by Cross et al.1 on the use of intra-operative frozen section for suspected early ovarian cancer. We would like to commend the authors for their work in providing these data and we recognise the need for mechanisms that can be used to address the National Institute for Health and Clinical Excellence (NICE) Guidelines CG122, which recommend assessment of the para-aortic lymph nodes in women with early ovarian cancer.2
However, there are a number of areas of practice that we feel need to be examined further before frozen section procedures can be used to alter the management of women with suspected early-stage ovarian cancer.
First, we are perplexed that the authors deemed it necessary to undertake para-aortic lymphadenectomy for women with borderline ovarian tumours. These are by nature an unpredictable class of tumour with mostly good outcomes and little in the way of nonsurgical treatment options when there is disseminated disease. Further, they are usually early-stage tumours and so the utility of a para-aortic lymph node dissection is questionable. If the authors had described the rate of disease in lymph nodes and the difference in outcome this provided for the woman with positive nodes their data would lend stronger support for more widespread implementation.
Accepting this and examining the authors data for ‘all comers’ (Table 1) we calculate that 28.8% (415) of women had an appropriate para-aortic lymph node dissection on the basis of the frozen section prediction, which represents the real-world scenario for the gynaecological oncology surgeon waiting in theatre for a frozen section analysis to be phoned back.
If the authors changed their protocol to only using dissection in women with malignancy on frozen section, 63.8% (918) of women would appropriately not undergo a para-aortic dissection. The total number of women correctly triaged by frozen section analysis would be 92.6%. Of the remainder, 7% would not undergo a para-aortic dissection that should and 0.35% would have a dissection they do not need. Such a protocol change compares with the authors’ figures who, when including a policy of para-aortic dissection for borderline tumours on frozen section, overtreated 8% of the women and undertreated 1.3%.
The answer to deciding which strategy one would wish to take up must come down to the differences in outcome for these women, defined by morbidity and mortality comparisons from overtreatment or undertreatment by surgery or chemotherapy, respectively, and any subsequent influence this has on overall survival. Unfortunately the authors do not provide this information, and only allude to data in preparation that indicate their ability to increase the stage of a woman’s disease. However, this figure can be calculated from their data in Table 1 to equate to 82 women (5.7%) who had a frozen section showing borderline disease but whose final paraffin section report showed a malignancy. Until other centres can validate their techniques and such practice can be shown to translate into a survival benefit for women, it is unlikely that their data will change surgical practice in women with early ovarian cancer.

References

  • 1
    Cross P, Naik R, Patel A, Nayar A, Hemming J, Williamson S, et al. Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience. BJOG 2012;119:194201.
  • 2
    National Institute for Health and Clinical Excellence. The recognition and initial management of ovarian cancer. [http://www.nice.org.uk/CG122]. Accessed 20 January 2012. 

Friday, May 11, 2012

paywalled: (re: juice plus) Gynecologic Oncology - A randomized parallel-group dietary study for stages II–IV ovarian cancer survivors



 Blogger's Note: reference prior posting (juice plus) noting that the audio indicated that the study was done on those ovarian cancer survivours without active disease, not indicated in this abstract (defining cancer survivors?); as well, not indicated (needs confirmation) in the audio is that the study size was small at 51 patients

ScienceDirect.com - Gynecologic Oncology - A randomized parallel-group dietary study for stages II–IV ovarian cancer survivors

A randomized parallel-group dietary study for stages II–IV ovarian cancer survivors 



Abstract

Objective

Few studies have examined the dietary habits of ovarian cancer survivors. Therefore, we conducted a study to assess the feasibility and impact of two dietary interventions for ovarian cancer survivors.

Methods

In this randomized, parallel-group study, 51 women (mean age, 53 years) diagnosed with stages II–IV ovarian cancer were recruited and randomly assigned to a low fat, high fiber (LFHF) diet or a modified National Cancer Institute diet supplemented with a soy-based beverage and encapsulated fruit and vegetable juice concentrates (FVJCs). Changes in clinical measures, serum carotenoid and tocopherol levels, dietary intake, anthropometry, and health-related quality of life (HRQOL) were assessed with paired t-tests.

Results

The recruitment rate was 25%, and the retention rate was 75% at 6 months. At baseline, 28% and 45% of women met guidelines for intake of fiber and of fruits and vegetables, respectively. After 6 months, total serum carotenoid levels and α- and β-carotene concentrations were significantly increased in both groups (P < 0.01); however, β-carotene concentrations were increased more in the FVJC group. Serum β-cryptoxanthin levels, fiber intake (+ 5.2 g/day), and daily servings of juice (+ 0.9 servings/day) and vegetables (+ 1.3 servings/day) were all significantly increased in the LFHF group (all P < 0.05). Serum levels of albumin, lutein and zeaxanthin, retinol, and retinyl palmitate were significantly increased in the FVJC group (all P < 0.05). No changes in cancer antigen-125, anthropometry, or HRQOL were observed.

Conclusion

Overall, this study supports the feasibility of designing dietary interventions for stages II–IV ovarian cancer survivors and provides preliminary evidence that a low fat high fiber diet and a diet supplemented with encapsulated FVJC may increase phytonutrients in ovarian cancer survivors.

Highlights

► Many ovarian cancer survivors fail to meet current guidelines for dietary intake.
► A low-fat diet supplemented with encapsulated fruit and vegetable juice concentrates can improve carotenoid levels.
► Encapsulated fruit and vegetable juice concentrates may help bridge the gap between what is consumed and what is needed.

22 min audio: (in patients without active cancer) Explanation of the Study Published in “Gynecologic Oncology” by Richard C. Boronow, MD (AUDIO) | TheBeavers.net - Juice Plus



Explanation of the Study Published in “Gynecologic Oncology” by Richard C. Boronow, MD (AUDIO) | TheBeavers.net - Juice Plus

Explanation of the Study Published in “Gynecologic Oncology” by Richard C. Boronow, MD (AUDIO)

NMD Presentation Phoenix FINAL 24
Richard Boronow, MD explains one of the latest studies on Juice Plus recently published in the “Gynecologic Oncology” Journal.
20:11
22:04

About Curt Beavers

Atlanta, GA native and graduate of Georgia Tech, Curt is married to Lori with 3 great kids. Owns International Virtual Franchise with Juice Plus... has fun running, reading, all things Apple (Macbook, iPhone, iPad), travel, hunting and being with family.

Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron



Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron

Background: Chronic diseases reduce the availability of iron for effective erythropoiesis. This review summarises clinical consequences of iron deficiency (ID) and anaemia in cancer patients, mechanisms how impaired iron homeostasis affects diagnosis and treatment of ID, and data from clinical trials evaluating i.v. iron with or without concomitant erythropoiesis-stimulating agents (ESAs).......

Blogger's Note: table includes solid tumors

Table 1.
Reported prevalence of iron deficiency in different cancer patient populations

"potential role for i.v. iron as first-line therapy for CIA?
Guidelines recommend treatment of underlying causes of anaemia such as ID before initiation of an ESA. However, studies examining i.v. iron as sole anaemia treatment in cancer patients are only just starting to emerge. Two relevant small (N = 44 and 75 patients), controlled, randomised clinical trials have been published. Both studies involved patients with gynaecologic cancers receiving chemotherapy or radiochemotherapy, and in both, i.v. iron supplementation significantly reduced the number of required blood transfusions [15, 16]. In one study, significantly higher Hb levels were observed in the i.v. iron compared with the oral iron group at the end of the study period, although mean Hb levels included data from patients who received transfusions as well as those who did not [15]. The other study, comparing i.v. iron versus no anaemia treatment, achieved a lower rate in transfusions despite a higher baseline proportion of anaemic patients in the study group [16]. Both studies missed to assess iron status parameters such as TSAT and serum ferritin; thus, the proportion of patients with either functional or absolute ID could not be determined."

cross references:
  1. 15.
    1. 16.
       Concluding remarks
      The high prevalence of ID and anaemia in cancer patients suggests that these complications may need more attention in clinical practice. Current guidelines for treating anaemic cancer patients recommend that ID should be considered as underlying cause of anaemia before initiating ESA treatment and acknowledge that i.v. iron supplementation is superior to oral iron. .....................Published randomised controlled trials show that i.v. iron enhances response rates to ESA therapy and may be effective in reducing ESA doses and blood transfusion requirements, even if long-term safety remains to be examined. Available early reports on the use of i.v. iron as first-line anaemia therapy suggest that some patients could benefit from i.v. iron even without concomitant ESA. However, larger randomised controlled studies with long-term follow-up are necessary to confirm long-term efficacy and safety.

paywalled: Dietary Supplements and Cancer Prevention: Balancing Potential Benefits Against Proven Harms



Dietary Supplements and Cancer Prevention: Balancing Potential Benefits Against Proven Harms

Abstract

Nutritional supplementation is now a multibillion-dollar industry, and about half of all US adults take supplements. Supplement use is fueled in part by the belief that nutritional supplements can ward off chronic disease, including cancer, although several expert committees and organizations have concluded that there is little to no scientific evidence that supplements reduce cancer risk. To the contrary, there is now evidence that high doses of some supplements increase cancer risk. Despite this evidence, marketing claims by the supplement industry continue to imply anticancer benefits. Insufficient government regulation of the marketing of dietary supplement products may continue to result in unsound advice to consumers. Both the scientific community and government regulators need to provide clear guidance to the public about the use of dietary supplements to lower cancer risk.

paywalled: Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: A meta-analysis



Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: A meta-analysis

Abstract 

Objectives

To compare the diagnostic performances of computed tomography (CT), magnetic resonance (MR) imaging, and positron emission tomography (PET or PET/CT) for detection of metastatic lymph nodes in patients with ovarian cancer.

Methods

Relevant studies were identified with MEDLINE and EMBASE from January 1990 to July 2010. We estimated the weighted summary sensitivities, specificities, OR (odds ratio), and summary receiver operating characteristic (sROC) curves of each imaging technique and conducted pair-wise comparisons using the two-sample Z-test. Meta-regression, subgroup analysis, and funnel plots were also performed to explain the between-study heterogeneity.

Results

Eighteen eligible studies were included, with a total of 882 patients. PET or PET/CT was a more accurate modality (sensitivity, 73.2%; specificity, 96.7%; OR [odds ratio], 90.32). No significant difference was detected between CT (sensitivity, 42.6%; specificity, 95.0%; OR, 19.87) and MR imaging (sensitivity, 54.7%; specificity, 88.3%; OR, 12.38). Meta-regression analyses and subgroup analyses revealed no statistical difference. Funnel plots with marked asymmetry suggested a publication bias.

Conclusion

FDG-PET or FDG-PET/CT is more accurate than CT and MR imaging in the detection of lymph node metastasis in patients with ovarian cancer.


paywalled: Same-Day Discharge in Clinical Stage I Endometrial Cancer Patients Treated with Total Laparoscopic Hysterectomy, Bilateral Salpingo-Oophorectomy and Bilateral Pelvic Lymphadenectomy



Blogger's Note/Opinion: while this is not ovarian cancer surgery but endometrial cancer surgery, the surgery described is the same; drive thru mastectomies, cancer surgeries - amazing really -  disgusting might be a more accurate term with a reminder that studies can and often do make policy, the abstract does not define many factors involved in gyn cancer surgeries and notable is the lack of any indication of followup period (of time), readmission rates (days) can vary depending on the hospital.....
                           ~~~~~~~~~~~~~~~~~

Same-Day Discharge in Clinical Stage I Endometrial Cancer Patients Treated with Total Laparoscopic Hysterectomy, Bilateral Salpingo-Oophorectomy and Bilateral Pelvic Lymphadenectomy

Clinical Study
Same-Day Discharge in Clinical Stage I Endometrial Cancer Patients Treated with Total Laparoscopic Hysterectomy, Bilateral Salpingo-Oophorectomy and Bilateral Pelvic Lymphadenectomy
Mark A. Rettenmaier, Alberto A. Mendivil, John V. Brown, III, Lisa N. Abaid, John P. Micha, Bram H. Goldstein

Gynecologic Oncology Associates, Newport Beach, Calif., USA

Address of Corresponding Author
Oncology 2012;82:321-326 (DOI: 10.1159/000337573)


  goto top of page Abstract
Objectives:

The purpose of this retrospective study was to evaluate the capacity for same-day discharge in clinical stage I endometrial cancer (EC) patients treated with total laparoscopic hysterectomy (TLH), bilateral salpingo-oophorectomy (BSO) and bilateral pelvic lymph node dissection (BPLND).  

Methods:
We retrospectively reviewed the charts of stage I EC patients who were treated with TLH, BSO and BPLND and discharged on the same day. The intra- and postoperative clinical variables (e.g., age, complications, surgery time, patient hospital stay) were evaluated in an attempt to discern which factors may predispose a patient to same-day discharge.

Results:
Twenty-one patients were successfully discharged on the same day of surgery. Mean operative time was 1.48 h and length of hospital stay was 6.35 h. There were no intraoperative complications or hospital readmissions.  

Conclusions:
We present a single, institutional experience solely assessing the capacity for same-day discharge in clinical stage I EC patients treated with TLH, BSO and BPLND. Since the postoperative complication rate was minimal with no hospital readmissions, we suggest that particularly selected stage I EC patients are amenable to outpatient management.
Copyright © 2012 S. Karger AG, Basel


 goto top of page Author Contacts
Bram H. Goldstein, PhD
Gynecologic Oncology Associates
351 Hospital Road, Suite 507
Newport Beach, CA 92663 (USA)
Tel. +1 949 642 5165, E-Mail bram@gynoncology.com

CancerWorld: Framing the argument over futile care - overdiagnose, overtreat, overpromise...media focus



Framing the argument over futile care:

We “overdiagnose, overtreat and overpromise”. This was the claim made by numerous newspaper headlines in response to the Lancet Oncology report last September on delivering affordable cancer care. While we do need open and frank discussions about how to curb the spiralling costs of cancer care, it was unfortunate that the media focused so heavily on the cost of futile treatment in the last weeks of life, blaming it all on a culture of excess. This sparked reports that patients would be denied potentially life-prolonging treatments purely on the basis of cost and generated fears that patients might be abandoned in their final months. There is no doubt that we do overtreat and overpromise in the advanced cancer setting. We know, for instance, that many patients receive cancer treatments in the last weeks of their life, and that some of these treatments have no reasonable chance of helping the patient and are associated with severe side-effects that can lead to hospitalisation and even death. We also know that receiving chemotherapy is associated with a delay in referral to palliative care. But blaming this on a culture of excess is too simplistic. Making the right decisions in later stages of advanced cancer is difficult for doctors and patients alike. It is often impossible to predict how long a patient will live, and while we have an increasing number of therapies to choose from, we don’t yet know enough about who stands to benefit and by how much. There can be a huge disconnect between the expectations of patients and families and those of clinicians, adding to the difficulty of conducting honest conversations with patients about their prognosis, treatment options and end-of-life preferences. There are no easy answers. But could we be making things harder for ourselves by posing options in terms of a choice between either fighting cancer or optimising quality of life? An emerging body of evidence shows that integrating palliative care into the mainstream care of cancer patients not only improves their quality of life, but might even help them live longer. Early involvement of palliative care specialists has also been shown to cut down on futile medical interventions and help families cope better with their loss of a loved one. ASCO is now recommending that patients should be offered concurrent palliative care and standard cancer treatments early in the course of their advanced cancer journey. This is in line with efforts to stimulate meaningful interaction between mainstream oncology and palliative care specialists that ESMO and other European professional bodies have been pursuing for some time. However, progress so far has been infuriatingly slow. Greater integration of palliative care requires changes in the way we organise care and train clinicians. We need to get on with this as a matter of urgency. If we fail to take a lead in addressing shortcomings in the way we care for patients with advanced cancer, the simplistic arguments about a wasteful culture of excess could win, and patients will be the losers.

Thursday, May 10, 2012

audio/video: Loud and Clear



Loud and Clear

In late fall 2011, The Change Foundation engaged Ontario seniors with chronic health conditions and their informal caregivers about their experiences with transitions in our healthcare system. This report is about their stories, experiences, and ideas.
Download Loud and Clear report PDF

Loud and Clear: seniors and caregivers speak out about navigating Ontario's healthcare system



Change Foundation engaged Ontario seniors.....

Loud and Clear




About Loud and Clear

In Loud and Clear: Seniors and caregivers speak out about navigating Ontario’s healthcare system, we explain our rationale for the timing and target of our engagement, describe our methodology, present our findings and how we plan to use them, and share the Foundation’s next steps and how they fit, feed into, and even blaze the way for patient-centred healthcare in Ontario.

Dedication

We dedicate this report to the seniors and their family members and friends across Ontario who shared their experiences and stories with us. They spoke forcefully and thoughtfully, with both emotion and measure, about where the system has failed them and how it could serve them better. They spoke loud and clear.

Connect. Communicate. Include.

“I don’t know what’s happening next, but where do you go to find the answers? Seems like there are roadblocks set up in the system that make it hard.”
Ontario senior 
 
“Our doctor sent us for an appointment with a specialist. We waited five months and never heard anything, so I called and they had no record of the appointment. It would be a good idea if someone from the doctor’s office called the patient once an appointment is made to confirm.”
Ontario senior 

“I’ve never been asked as a caregiver, 'What’s convenient for you?' Or 'How would this work in your family?' instead it’s 'This is what we’re going to do for you.' There's no discussion of collaboration.”
Ontario caregiver

Immunotherapy of cancer in 2012 - Kirkwood - 2012 - CA: A Cancer Journal for Clinicians - Wiley Online Library



Immunotherapy of cancer in 2012 - Kirkwood - 2012 - CA: A Cancer Journal for Clinicians

excerpt re: ovarian cancer:

Immunotherapy for Ovarian Cancer

Recent work has shown a correlation between increased survival and the presence of tumor-infiltrating effector-type lymphocytes in a given patient. The absence of tumor- infiltrating regulatory cells has supported the role of immune surveillance in the progression of ovarian cancer and provided additional rationale for immunotherapy for this aggressive disease. 314...............

Correspondence/Author's Response: Paraneoplastic Thrombocytosis in Ovarian Cancer — NEJM



Paraneoplastic Thrombocytosis in Ovarian Cancer — NEJM

Correspondence

Paraneoplastic Thrombocytosis in Ovarian Cancer

N Engl J Med 2012; 366:1840 May 10, 2012

To the Editor:

The mean platelet volume (MPV), analogous to the calculation of the mean corpuscular volume, is calculated as the plateletcrit divided by the total number of platelets. Although the MPV is readily available on a routine blood count, many laboratories do not report the MPV to clinicians because of the lack of standardization and the dependency of the results on the age of the sample and the method of measurement. Stone et al. (Feb. 16 issue)1 found that thrombocytosis was associated with shortened survival and advanced disease in patients with ovarian cancer. A recent population-based study has shown the MPV to be a predictor of venous thromboembolism.2 Other studies have shown the MPV to be a predictor of cardiovascular risk, with an elevated MPV associated with increased mortality after acute myocardial infarction and an increased rate of restenosis after coronary angioplasty.3 Similarly, an elevated MPV is associated with a worse outcome for acute ischemic cerebrovascular events, independent of other clinical factors.4 We would like to know whether the investigators obtained data on the MPV in their study cohort, and if so, whether they found any correlation between the MPV and survival, independent of thrombocytosis.
Harris V. Naina, M.D.
Samar Harris, M.D.
UT Southwestern, Dallas, TX
No potential conflict of interest relevant to this letter was reported.
4 References

Author/Editor Response

Platelet size, as measured by the MPV and platelet distribution width, correlates with platelet reactivity.1 Retrospective data suggest that the MPV has potential prognostic and diagnostic value in hematologic and cardiovascular disorders.2 However, it is not known whether the MPV is a useful prognostic marker in patients with cancer. Although the focus of our investigation was on the mechanisms and effect of thrombocytosis on clinical outcomes in ovarian cancer, in response to the inquiry from Naina and Harris, we examined the association among the MPV, thrombocytosis, and survival in 150 patients with newly diagnosed advanced epithelial ovarian cancer. In this data set, the median MPV was 8 fl (range, 6 to 11). MPV levels were inversely correlated with platelet count (r=–0.45, P<0.001). Survival rates were not associated with the MPV (where a high MPV was defined as an MPV greater than either the median or the cutoff value used by our institution [>10.4 fl]). The value of alternative cutoff levels for MPV for prognostic evaluation is unknown.
Rebecca L. Stone, M.D.
Vahid Afshar-Kharghan, M.D.
Anil K. Sood, M.D.
University of Texas M.D. Anderson Cancer Center, Houston, TX

Correspondence/Aurthor's Response: Thromboprophylaxis in Patients Receiving Chemotherapy — NEJM



Thromboprophylaxis in Patients Receiving Chemotherapy — NEJM

Correspondence

Thromboprophylaxis in Patients Receiving Chemotherapy

N Engl J Med 2012; 366:1839-1840May 10, 2012
Article

To the Editor:

In their article on the results of the SAVE-ONCO study (ClinicalTrials.gov number, NCT00694382), which showed that semuloparin reduced the risks of deep-vein thrombosis in the lower or upper limbs and pulmonary embolism among patients receiving chemotherapy for cancer, Agnelli and colleagues (Feb. 16 issue)1 do not mention the development of central-venous-catheter thrombosis. Indeed, deep-vein thrombosis related to a central venous catheter is a frequent complication, reported in 4% of patients with symptomatic events and 20 to 30% of patients with asymptomatic events detected by means of venography or ultrasonography; this complication is associated with the risk of pulmonary embolism and loss of central venous access.2 A recent Cochrane review did not show any efficacy of heparins or vitamin K antagonists for the prevention of central-venous-catheter thrombosis.3 Accordingly, national guidelines mention no prophylactic treatment; specifically, they recommend no prophylactic doses of low-molecular-weight heparin or low-dose warfarin.2 Only the placement of the distal tip of the central venous catheter at the junction between the superior vena cava and the right atrium, and insertion on the right side are indicated.2,4 Therefore, was central-venous-catheter thrombosis observed in the study, and was semuloparin an effective prophylactic treatment?
Claude Bachmeyer, M.D.
Jean-Charles Pellen, M.D.
Tenon Hospital, Paris, France
No potential conflict of interest relevant to this letter was reported.
4 References

Author/Editor Response

Bachmeyer and Pellen wonder whether central venous catheter–related thrombosis was observed in the study and whether semuloparin was an effective prophylactic treatment for this complication. In our study, a central venous catheter was present in 19.7% of patients in the semuloparin group and 18.8% of patients in the placebo group. Symptomatic deep-vein thrombosis of the upper limbs, including central-venous-catheter thrombosis, was part of the composite primary efficacy outcome. During the efficacy analysis period, symptomatic deep-vein thrombosis of the upper limbs occurred in 9 of 1604 patients in the placebo group (0.6%) and 3 of 1608 patients in the semuloparin group (0.2%) (hazard ratio, 0.33; 95% confidence interval, 0.07 to 1.18). All these patients had a central venous catheter. The risk reduction in deep-vein thrombosis of the upper limbs (including central-venous-catheter thrombosis) associated with semuloparin was consistent with the risk reduction in the other components of the composite primary efficacy outcome of the study, but the number of observed events is small.

Giancarlo Agnelli, M.D.
University of Perugia, Perugia, Italy

Alexander G.G. Turpie, M.D.
McMaster University, Hamilton, ON, Canada

Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long? — NEJM



Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long? — NEJM

Bisphosphonates for Osteoporosis — Where Do We Go from Here? — NEJM



Bisphosphonates for Osteoporosis — Where Do We Go from Here? — NEJM

Seth's Blog: Why ask why? (including one important hint)



Why ask why?

"Why?" is the most important question, not asked nearly enough.

Hint: "Because I said so," is not a valid answer.
  • Why does it work this way?
  • Why is that our goal?
  • Why did you say no?
  • Why are we treating people differently?
  • Why is this our policy?
  • Why don't we enter this market?
  • Why did you change your mind?
  • Why are we having this meeting?
  • Why not?

paywalled: (March 2012) Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach.



Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach

Abstract

The most definitive role of fluorodeoxyglucose (FDG)-PET/computed tomography (CT) at present is surveillance and detecting recurrence in patients who have completed primary therapy but demonstrate a rising serum tumor marker (e.g., CA-125 levels). In this scenario, PET/CT demonstrates high sensitivity and accuracy in detecting lesions that are otherwise challenging, and appears superior (with less interobserver variability) compared with CT alone. Despite the fact that peritoneal deposits may be missed by PET/CT, the overall performance is better than CT alone. FDG-PET does not play a significant additional role in the primary diagnosis of ovarian cancers; however, the role of combined PET/CT modality has recently begun to be re-explored for initial disease staging, particularly because PET/CT can pick up small unsuspected lesions and thereby provide a better disease assessment of the whole body in a single examination. The baseline PET/CT also subserves an important role for future monitoring of therapy response. Therapy monitoring by PET could help to optimize neoadjuvant therapy protocols and to avoid ineffective therapy in nonresponders early in its course, although PET/CT has cost-effectiveness issues that need further evaluation. The prognostic value of FDG-PET/CT has been investigated in the following areas: in the preoperative setting to predict optimal cytoreduction; to assess the value of a positive FDG-PET following primary surgery; and when employed as a replacement for second-look laparotomy following completion of primary surgery and chemotherapy. The data, although promising, are still sparse in all the three domains for a definite recommendation.


 

birthdays - Rocco and Patina



https://col123.mail.live.com/att/GetAttachment.aspx?tnail=0&messageId=1b0577eb-9a39-11e1-a5c0-00237de3f558&Aux=2044|0|8CEFC5D042C0350||0|1|0|0|1|5,53&maxwidth=220&maxheight=160&size=Att

2012 Canadian Cancer Statistics - 5th ranking in women dying of cancer in Canada



2012 Report Canadian Cancer Statistics


new cases - 2,600 deaths - 1,750

8th ranking in # of new cases of cancers in women

5th ranking in # deaths of cancers in women


paywalled: Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel



Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients:

Background:
To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment.

Conclusion:
Permanent and severe alopecia is a newly reported complication of the FEC 100–docetaxel breast cancer regimen.

DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain - Drugs.com



http://tinyurl.com/7tmt942

DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain

"....Previous analyses of the study data were based predominantly on patient-reported Numeric Rating Scale (NRS) pain scores collected by healthcare professionals in a clinic setting during weekly visits, whereas this new analysis focused specifically on self-reported daily pain scores from patients' diaries. Responders in this analysis were defined as patients attaining a clinically-meaningful (at least 20%) improvement in mean NRS scores from baseline within any given week. Of the 12 patients who received KRN5500 in this 19-patient trial, 7 (58%) were classified as responders. Further, 5 of the 7 (71%) showed sustained pain relief over several weeks. Of the 7 patients who received placebo, none were responders. Therefore, the new analysis showed a temporal consistency of pain relief in a larger fraction of patients than had been noted in the earlier analysis of weekly clinic-reported pain. These findings are impressive since patients enrolled in this proof-of-concept trial had unrelenting pain at baseline despite the concomitant use of other approved analgesic agents........

 

Beware the creeping cracks of bias (in science research) : Nature News & Comment



Beware the creeping cracks of bias : Nature News & Comment

Long-Term Use of Osteoporosis Medication May Reduce Bone Fracture Risk for Some Patients - U California



Long-Term Use of Osteoporosis Medication May Reduce Bone Fracture Risk for Some Patients:

"Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it. Based on available evidence, a UCSF researcher reevaluated his 2006 finding from a randomized 10-year study of alendronate, a type of bisphosphonate - a class of drugs that prevent loss of bone mass.....

New Cautions About Bisphosphonates - NYTimes.com



New Cautions About Bisphosphonates - NYTimes.com

Wednesday, May 09, 2012

paywalled: The Predictive Capacity of Personal Genome Sequencing - Science Translational Medicine



[Research Articles] The Predictive Capacity of Personal Genome Sequencing:

New DNA sequencing methods will soon make it possible to identify all germline variants in any individual at a reasonable cost. However, the ability of whole-genome sequencing to predict predisposition to common diseases in the general population is unknown. To estimate this predictive capacity, we use the concept of a "genometype." A specific genometype represents the genomes in the population conferring a specific level of genetic risk for a specified disease. Using this concept, we estimated the maximum capacity of whole-genome sequencing to identify individuals at clinically significant risk for 24 different diseases.

PLoS ONE: Citizen Participation in Patient Prioritization Policy Decisions: An Empirical and Experimental Study on Patients' Characteristics



PLoS ONE: Citizen Participation in Patient Prioritization Policy Decisions: An Empirical and Experimental Study on Patients' Characteristics

"The results of the survey questions showed that the vast majority of respondents agreed to prioritize patients with life threatening diseases and patients with acute diseases over all other patients. All criteria that described the patient's social engagement outside the family or socio-economic status (e.g., income, unemployment) were rejected as possible criteria for prioritization. A similar pattern could be observed in the discrete choice experiment: health status received the highest importance weight, whereas socio-economic status received a very low weight in terms of deciding which patient should be treated first. There is considerable agreement that those in need, i.e., the severely ill patient, should be treated first [1], [5][7]. Socio-economic status was not considered acceptable, but is a commonly practiced criterion in the daily routine of physicians [40], if not explicitly, at least implicitly so [41], [42]."


"In particular, medical criteria are highly accepted for prioritizing patients whereas socio-economic criteria and lifestyles are rejected. Especially the DCE showed that health status and quality of life were the only attributes that respondents would ultimately likely include in a decision-making process about which patients to prioritize for care. Policy makers in Germany have been very reluctant to even discuss the topic; indeed, all ministers of health over the last decade or so have refused to even talk about this issue. The present study shows that the “voice of the patient” – reliably captured through the methods used here – can be encapsulated in statistical models and thus introduced into policy-making settings [15]. The methods and findings illustrated in this research can be used to 1) increase citizen participation in the political discussion concerning this substantive policy topic, 2) define the scope of policy actions within the realm of the feasible, and 3) frame communications between policy-setting bodies and the population."

paywalled: Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy




Diathermy: In the natural sciences, the term diathermy means "electrically induced heat" and is commonly used for muscle relaxation. It is also a method of heating tissue electromagnetically or ultrasonically for therapeutic purposes in medicine.





Diathermy-Induced Injury May Affect Detection of Occult Tuba... : International Journal of Gynecological Cancer

Background: Electrosurgery-induced tubal thermal injury obscures cellular detail and hampers histomorphological assessment for occult pathology.

Objective
The objectives of this study were to report on diathermy-related thermal injuries to the fallopian tube observed at RRSO and explore its potential impact on the detection of occult tubal epithelial lesions.

Design
This study was composed of high-risk women from breast and/or ovarian cancer families attending a tertiary high-risk familial gynecologic cancer clinic. This was a retrospective case-control analysis of high-risk women who underwent RRSO. Cases were all women detected to have occult lesions (tubal atypia/carcinoma in situ/cancer) between January 2005 and December 2010. Control subjects were all women with normal tubal/ovarian histology between August 2006 and December 2007.

Conclusions: This report highlights the potential impact of electrosurgical thermal injury on detection of occult tubal pathology following RRSO. It is important for surgeons to avoid thermal injury to the distal end of the tube.